FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113648081> ?p ?o ?g. }

• W2113648081 endingPage "2849" @default.
• W2113648081 startingPage "2842" @default.
• W2113648081 abstract "We studied T-BiRD (thalidomide [Thalomid(®)], clarithromycin [Biaxin(®)], lenalidomide [Revlimid(®)] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma. In 28-day cycles, patients received dexamethasone 40 mg/day on days 1, 8, 15, 22, clarithromycin 500 mg twice daily on days 1-28; lenalidomide 25 mg/day on days 1-21; and thalidomide 100 mg/day (50 mg/day on days 1-7 of cycle 1 only) on days 1-28. Twenty-six patients received a median of 6 cycles (range 0-41). Overall response rate (ORR) was 80% for the group and 100% in 11 patients who underwent autologous stem cell transplantation as part of first-line therapy. The 4-year overall survival rate was 74.9%, and the median progression-free survival was 35.6 months. Eight patients discontinued due to regimen toxicity. Grade 3 non hematologic toxicity affected 12 patients (46.2%). T-BiRD is a highly active regimen with potential toxicity limitations. ClinicalTrials.gov identifier: NCT00538733." @default.
• W2113648081 created "2016-06-24" @default.
• W2113648081 creator A5000554189 @default.
• W2113648081 creator A5014718917 @default.
• W2113648081 creator A5014809903 @default.
• W2113648081 creator A5028248272 @default.
• W2113648081 creator A5040549121 @default.
• W2113648081 creator A5047805762 @default.
• W2113648081 creator A5054599046 @default.
• W2113648081 creator A5056839401 @default.
• W2113648081 creator A5061867174 @default.
• W2113648081 creator A5062559413 @default.
• W2113648081 creator A5068215001 @default.
• W2113648081 creator A5077846750 @default.
• W2113648081 creator A5082720713 @default.
• W2113648081 creator A5083277645 @default.
• W2113648081 date "2014-03-25" @default.
• W2113648081 modified "2023-09-26" @default.
• W2113648081 title "Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma" @default.
• W2113648081 cites W1969648097 @default.
• W2113648081 cites W1973936169 @default.
• W2113648081 cites W2013370486 @default.
• W2113648081 cites W2015884113 @default.
• W2113648081 cites W2032640560 @default.
• W2113648081 cites W2035992346 @default.
• W2113648081 cites W2036200625 @default.
• W2113648081 cites W2039496823 @default.
• W2113648081 cites W2044436186 @default.
• W2113648081 cites W2055338149 @default.
• W2113648081 cites W2056172893 @default.
• W2113648081 cites W2064601405 @default.
• W2113648081 cites W2065859796 @default.
• W2113648081 cites W2079738711 @default.
• W2113648081 cites W2090310344 @default.
• W2113648081 cites W2104210520 @default.
• W2113648081 cites W2113101033 @default.
• W2113648081 cites W2114217833 @default.
• W2113648081 cites W2120161314 @default.
• W2113648081 cites W2120474651 @default.
• W2113648081 cites W2142368474 @default.
• W2113648081 cites W2144531125 @default.
• W2113648081 cites W2144831605 @default.
• W2113648081 cites W2146607984 @default.
• W2113648081 cites W2148188974 @default.
• W2113648081 cites W2161817637 @default.
• W2113648081 cites W2168929741 @default.
• W2113648081 cites W2169336006 @default.
• W2113648081 cites W4233598358 @default.
• W2113648081 doi "https://doi.org/10.3109/10428194.2014.896005" @default.
• W2113648081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24576165" @default.
• W2113648081 hasPublicationYear "2014" @default.
• W2113648081 type Work @default.
• W2113648081 sameAs 2113648081 @default.
• W2113648081 citedByCount "8" @default.
• W2113648081 countsByYear W21136480812015 @default.
• W2113648081 countsByYear W21136480812017 @default.
• W2113648081 countsByYear W21136480812018 @default.
• W2113648081 countsByYear W21136480812019 @default.
• W2113648081 countsByYear W21136480812021 @default.
• W2113648081 crossrefType "journal-article" @default.
• W2113648081 hasAuthorship W2113648081A5000554189 @default.
• W2113648081 hasAuthorship W2113648081A5014718917 @default.
• W2113648081 hasAuthorship W2113648081A5014809903 @default.
• W2113648081 hasAuthorship W2113648081A5028248272 @default.
• W2113648081 hasAuthorship W2113648081A5040549121 @default.
• W2113648081 hasAuthorship W2113648081A5047805762 @default.
• W2113648081 hasAuthorship W2113648081A5054599046 @default.
• W2113648081 hasAuthorship W2113648081A5056839401 @default.
• W2113648081 hasAuthorship W2113648081A5061867174 @default.
• W2113648081 hasAuthorship W2113648081A5062559413 @default.
• W2113648081 hasAuthorship W2113648081A5068215001 @default.
• W2113648081 hasAuthorship W2113648081A5077846750 @default.
• W2113648081 hasAuthorship W2113648081A5082720713 @default.
• W2113648081 hasAuthorship W2113648081A5083277645 @default.
• W2113648081 hasConcept C126322002 @default.
• W2113648081 hasConcept C141071460 @default.
• W2113648081 hasConcept C2776063141 @default.
• W2113648081 hasConcept C2776364478 @default.
• W2113648081 hasConcept C2776409635 @default.
• W2113648081 hasConcept C2776962512 @default.
• W2113648081 hasConcept C2778570526 @default.
• W2113648081 hasConcept C2779050716 @default.
• W2113648081 hasConcept C2779609412 @default.
• W2113648081 hasConcept C2780401358 @default.
• W2113648081 hasConcept C2781413609 @default.
• W2113648081 hasConcept C2911091166 @default.
• W2113648081 hasConcept C29730261 @default.
• W2113648081 hasConcept C71924100 @default.
• W2113648081 hasConcept C90924648 @default.
• W2113648081 hasConceptScore W2113648081C126322002 @default.
• W2113648081 hasConceptScore W2113648081C141071460 @default.
• W2113648081 hasConceptScore W2113648081C2776063141 @default.
• W2113648081 hasConceptScore W2113648081C2776364478 @default.
• W2113648081 hasConceptScore W2113648081C2776409635 @default.
• W2113648081 hasConceptScore W2113648081C2776962512 @default.
• W2113648081 hasConceptScore W2113648081C2778570526 @default.
• W2113648081 hasConceptScore W2113648081C2779050716 @default.
• W2113648081 hasConceptScore W2113648081C2779609412 @default.

• next